Igenbio Provides Automated Variant Analysis

CHICAGO--(BUSINESS WIRE)--Igenbio, Inc. announced today the expansion of variant analysis service offerings. Igenbio’s comprehensive variant analysis service answers pressing questions in genome differences reflecting changes to metabolic pathways and genetic associations relevant to disease- or cancer-causing variations. Igenbio’s flagship product ERGO 2.0 enables researchers to deepen the analysis of variations with interactive visualizations enabling industrial, academic, and medical scientists to rapidly uncover hidden genetic variations and develop diagnostic biomarkers.

“Research scientists can use ERGO’s Variant workflow by simply “dragging-and-dropping” the sequence files into ERGO and receiving scientifically rigorous results in minutes. Discover single nucleotide polymorphisms (SNPs), insertions, deletions (INDELS), along with their functional relevance and deleterious effects. ERGO does it all for you: from sequence quality assessments to annotating variant effects of any genome. This furthers our goal of making the best bioinformatics analysis available to all researchers, regardless of their computer experience.”, says Benjamin Vaisvil, VP, Bioinformatics and Software Development at Igenbio, Inc.

About Igenbio

Chicago-based Igenbio, Inc. specializes in research in genomics, bioinformatics, and transcriptomics. Igenbio, Inc. serves a broad customer base across industry, academic and government institutions. ERGO 2.0 integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, with tools and workflows for common bioinformatics tasks. Our goal is to make the best scientific analysis available to all researchers.

Igenbio Expands Its Offerings in Microbial Community Analysis

February 13, 2018 04:27 PM Eastern Standard Time
CHICAGO--Igenbio, Inc. announced today the expansion of metagenomics service offerings to include microbial community profiling, and microbial community metabolic analysis. Igenbio’s microbial community analysis service helps answer pressing questions in microbiome, environmental, and clinical studies. Igenbio’s scientists’ expertise streamlines the development of custom assays which efficiently answer specific research questions. Analysis offerings range from rRNA analysis, to whole metagenome sequencing, and qPCR. Igenbio’s flagship product ERGO 2.0 enables researchers to deepen the analysis of expression data on interactive exportable metabolic pathway visualizations enabling industrial, academic, and medical scientists to rapidly discover and develop diagnostic biomarkers.

Read More

Igenbio, Inc. services expand into human genome and expression analytics

CHICAGO--Igenbio, Inc., a genomics and informatics solutions provider, has expanded its service offerings into the human genome analytics market. With its flagship cloud-based Software as a Service (SaaS) analytics platform ERGO, known in the microbial and synthetic biology spaces, Igenbio, Inc. now offers human genome RNA sequence analytics. ERGO provides fully featured coding and non-coding gene expression analytics for RNA-Seq. ERGO's human analytics module is easy to use and surpasses present desktop software offerings for computing differential gene expression, clustering, and variant detection. “ERGO frees scientists from the costly hassle of complex data and software management,” said Vinayak Kapatral Ph.D. President, CEO of Igenbio, Inc.

Read More

Igenbio, Inc. Releases ERGO 2.0

Igenbio, Inc. announced today the release of ERGO 2.0, the latest version of a unique integrated platform that enables industrial, academic, and medical scientists to rapidly develop knowledge from existing and new DNA sequencing projects. ERGO 2.0 will help reduce time to market by saving precious lab effort and resources. ERGO 2.0 contains a massive curated database integrated with state of the art synthetic biology tools enabling faster product creation.

Read More

Focus Ahead Consulting to Represent Integrated Genomics' Products and Services in Europe

Arlington Heights, IL (February 9, 2010) Integrated Genomics, Inc., a leader in microbial genomic informatics, is collaborating with Focus Ahead Consulting Ltd. in the UK to represent and market microbial genome sequencing and bioinformatics services in Europe. Integrated Genomics ERGO™ platform is the leading informatics system for microbial systems biology. 

Read More

Integrated Genomics, Inc. Appoints Jose Laplaza, Ph.D. as Director of Strain Engineering and Lab Operations

CHICAGO, IL (May 5, 2009) – Integrated Genomics, Inc. today announces it has appointed Jose Laplaza, Ph.D. as Director of Strain Engineering and Lab Operations. Dr. Laplaza brings significant experience in gene expression, fermentation optimization and strain development. He will be responsible for leading IG’s efforts in contract and internal metabolic engineering research. 

Read More

TMO Renewables and Integrated Genomics Extend Cellulosic Ethanol Research Collaboration

(Chicago, IL and Guildford, UK) Integrated Genomics, Inc., a leader in microbial genomic informatics and TMO Renewables Limited, a leader in the production of ethanol from biomass, announced today that they have signed an agreement to extend their collaboration on the discovery of cellulosic bioethanol production systems. 

Read More

P&G Completes Genome Sequence of Fungus Responsible for Dandruff, Skin Disorders

Cincinnati, OH - Scientists from P&G Beauty announced that they successfully sequenced the complete genome for Malassezia globosa (M. globosa), a naturally occurring fungus responsible for the onset of dandruff and other skin conditions in humans. Results of the genome sequencing are published in the November fifth online edition of Proceedings of the National Academy of Sciences (PNAS).

Read More

BIOBASE and Integrated Genomics Ink Curation Agreement

(Chicago IL, Beverly MA, and Wolfenbüttel Germany) Integrated Genomics Inc. and BIOBASE GmbH announced today that they have signed a collaboration agreement to expand and curate Integrated Genomics' ERGO™ microbial genomic database. BIOBASE scientists in Bangalore, India will add manually-curated functional gene annotations and pathways to the ERGO genomic database. This agreement further expands the custom curation services BIOBASE offers its customers.

Read More

Korean Research Institute of Bioscience and Biotechnology licenses ERGO™ genomics platform to identify biological products in microbes

(Chicago, IL and Daejeon, South Korea) Korean research Institute of Bioscience and Biotechnology (KRIBB), a world leader in the integrated biotechnology and bioinformatics has licensed the ERGO™ bioinformatics software developed and maintained by Integrated Genomics. KRIBB will utilize the ERGO™ genome analysis tools for gene annotation, metabolic reconstruction and enzyme data-mining as well as for comparative genomics purposes.

Read More

TMO Renewables licenses ERGO genomics platform to enhance cellulosic ethanol production using microbial genomes

(Chicago, IL and Guildford, UK) TMO Renewables Limited, a leader in the production of ethanol from biomass, has licensed the ERGO™ bioinformatics software developed and maintained by Integrated Genomics. TMO will utilize the ERGO™ genome analysis tools for gene annotation, metabolic reconstruction and enzyme data-mining as well as comparative genomics. 

Read More

New England Biolabs licenses ERGO genomics platform to identify novel enzymes and biological products in microbes

New England Biolabs (NEB), a world leader in the production and supply of reagents for the life science industry, has licensed the ERGO™ bioinformatics software developed and maintained by Integrated Genomics. NEB will utilize the ERGO™ genome analysis tools for gene annotation, metabolic reconstruction and enzyme data-mining as well as for comparative genomics purposes. 

Read More

Oxford Gene Technology and Integrated Genomics to Develop a Pichia pastoris Gene Expression Microarray

CHICAGO, IL and Oxford, UK - March 6, 2007

Oxford Gene Technology (OGT) and Integrated Genomics (IG) today announced the signing of a collaboration to develop and market a Pichia pastoris Gene Expression (GE) oligonucleotide microarray. The collaboration gives OGT access to IG’s proprietary Pichia pastoris genomic sequence for the design and development of a high quality optimized 60 mer oligonucleotide microarray using the ink jet in-situ synthesis (IJISS) platform. OGT will market the array worldwide, and offer a sample analysis service at its Oxford laboratory.

Read More